English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/134820
Share/Impact:
Statistics
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL
Exportar a otros formatos:
Title

ColoLipidGene: signature of lipid metabolism-related genes to predict prognosis in stage-II colon cancer patients

AuthorsVargas, Teodoro; Mendiola, Marta; Risueño, A.; De Las Rivas, Javier ; Maurel, Joan; Ramírez de Molina, Ana
KeywordsColon cancer
Biomarker
Prognosis
Lipid metabolism
Issue Date2015
PublisherImpact Journals
CitationOncotarget 6(9): 7348-7363 (2015)
AbstractLipid metabolism plays an essential role in carcinogenesis due to the requirements of tumoral cells to sustain increased structural, energetic and biosynthetic precursor demands for cell proliferation. We investigated the association between expression of lipid metabolism-related genes and clinical outcome in intermediate-stage colon cancer patients with the aim of identifying a metabolic profile associated with greater malignancy and increased risk of relapse. Expression profile of 70 lipid metabolism-related genes was determined in 77 patients with stage II colon cancer. Cox regression analyses using c-index methodology was applied to identify a metabolic-related signature associated to prognosis. The metabolic signature was further confirmed in two independent validation sets of 120 patients and additionally, in a group of 264 patients from a public database. The combined analysis of these 4 genes, ABCA1, ACSL1, AGPAT1 and SCD, constitutes a metabolic-signature (ColoLipidGene) able to accurately stratify stage II colon cancer patients with 5-fold higher risk of relapse with strong statistical power in the four independent groups of patients. The identification of a group of 4 genes that predict survival in intermediate-stage colon cancer patients allows delineation of a high-risk group that may benefit from adjuvant therapy, and avoids the toxic and unnecessary chemotherapy in patients classified as low-risk group.
DescriptionThis is an open-access article distributed under the terms of the Creative Commons Attribution License.
This is a collaborative study between the Molecular Oncology Unit of The Institute of Advanced Studies of Madrid IMDEAFood and the Grupo Español Multidisciplinar en Cáncer Digestivo (GEMCAD).-- et al.
Publisher version (URL)http://dx.doi.org/10.18632/oncotarget.3130
URIhttp://hdl.handle.net/10261/134820
DOI10.18632/oncotarget.3130
Identifiersdoi: 10.18632/oncotarget.3130
e-issn: 1949-2553
Appears in Collections:(IBMCC) Artículos
Files in This Item:
File Description SizeFormat 
ColoLipidGene.pdf1,96 MBAdobe PDFThumbnail
View/Open
Show full item record
Review this work
 

Related articles:


WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.